WAYNE, Pa. and LEUSDEN, Netherlands, Oct. 26 /PRNewswire/ -- Molecular Detection Inc. (MDI), a company developing Detect-Ready™ tests designed to increase the speed and accuracy of infectious disease diagnosis, and life sciences and diagnostics distributor Westburg BV today announced that they have entered into an exclusive agreement for distribution of MDI's Detect-Ready MRSA panel in the Benelux region. The Detect-Ready panel offers healthcare providers a high-performance MRSA screening test with an unmatched combination of accuracy, speed, flexibility and cost-effectiveness. This new agreement adds to MDI's growing global network of leading distribution partners.
"This agreement with Westburg extends our strategy of partnering our Detect-Ready MRSA test with major distributors in key territories around the globe," said David Wilson, MDI's vice president for commercial operations, Europe. "Westburg's record of providing high quality scientific products to a growing number of end-user markets and their commitment to exceptional customer service will support acceptance of the Detect-Ready panel in the Netherlands, Belgium and Luxembourg. We anticipate launch in the Benelux region shortly, at which time our Detect-Ready MRSA panel will be available in 10 markets worldwide."
Separately, MDI announced that its Detect-Ready test has been renamed the Detect-Ready MRSA panel in recognition of the fact that it is now CE-marked in the European Union for the detection of MRSA (methicillin-resistant Staphylococcus aureus), methicillin-sensitive S. aureus (MSSA), methicillin-resistant non-S. aureus and mixed samples, which are frequently encountered in actual clinical practice. MSSA refers to S. aureus infections that can be treated with standard antibiotics. Both MRSA and MSSA infections pose a growing problem to healthcare facilities and their patients. A s
|SOURCE Molecular Detection Inc.|
Copyright©2010 PR Newswire.
All rights reserved